FORCE and researchers at the University of South Florida formed the ABOUT Patient-Powered Network to help advance hereditary cancer research through collaborations. See below for more information about each project, FORCE's role, and the status of the research.
Women Choosing Surgical Prevention (WISP) Trial

Research Cycle:
Evaluate

Lead Researcher:
Karen H. Lu, MD M.D. Anderson Cancer Center

Type of Research:
Cancer Screening and Prevention,Quality of Life

Women Choosing Surgical Prevention (WISP) Trial

Background

National expert guidelines recommend removal of the ovaries and fallopian tubes after childbearing is complete for women at high risk for ovarian cancer due to an inherited mutation. This surgery can lead to early-onset menopause and associated symptoms and side effects. Research suggests that many ovarian cancers in mutation carriers may begin in the fallopian tubes. Researchers are studying whether removal of the fallopian tubes only followed by removal of the ovaries closer to menopause may be a safe alternative that improves quality of life for women with mutations. 

Goals of the study

The goal of the WISP Study is to compare whether removal of fallopian tubes only, delaying removal of the ovaries can safely improve sexual functioning and menopausal symptoms compared to standard risk-reducing removal of the ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy or RRSO). 

FORCE and ABOUT Network role

FORCE advocates have been involved with WISP from the start of the study until now. We participated in the development of the study surveys, communications and consent forms and have actively helped recruitment for the study through our website, mailing list and social media outreach. Now that enrollment has closed, FORCE will continue to provide our community with updates on study findings.

This research is relevant for:

People who test positive for an inherited mutation

People at high risk for ovarian cancer